News
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
Relief Therapeutics Announces Executive Leadership Team Change
Relief Therapeutics Announces Executive Leadership Team Change
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
Relief Therapeutics Provides an Update on its Financing Strategy
Relief Therapeutics Provides an Update on its Financing Strategy
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements